Dermatologicals
Refine Search
Pharmaceutical
LEO Pharma has entered into an asset purchase agreement under which Japanese drug major Astellas Pharma will transfer its global dermatology business to LEO. 11 November 2015
Pharmaceutical
New market research titled "EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024" says atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022, at a compound annual growth rate (CAGR) of 3.8%. 11 November 2015
Pharmaceutical
Spain’s largest pharma company Almirall today announced year-to-date financial results, showing that total revenues for the first nine months of 2015 were 595.3 million euros ($640.8 million). 9 November 2015
Pharmaceutical
LEO Pharma said today that its Enstilar (calcipotriene/betamethasone dipropionate) foam has been approved by the US Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older. 19 October 2015
Pharmaceutical
US pharma giant Pfizer says it has received a complete response letter from the US Food and Drug Administration for its supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) for the treatment of adult patients with moderate to severe chronic plaque psoriasis. 15 October 2015
Biotechnology
US biotech firm Celgene Corp via its unit Celgene International Sàrl, said its Otezla (apremilast), to treat plaque psoriasis has shown meaningful improvements. 13 October 2015
Biosimilars
The US Food and Drug Administration (FDA) has accepted the regulatory application by Swiss drug major Novartis’ generics unit Sandoz, for a biosimilar version of Amgen's Enbrel (etanercept). 2 October 2015
Biotechnology
Late stage trials for by Anglo-Swedish drug major AstraZeneca’s brodalumab, to treat moderate to severe psoriasis, have shown positive results, according to a report published by the New England Journal of Medicine (NEJM). 1 October 2015
Pharmaceutical
XenoPort had a roller-coaster morning after it announced positive preliminary top-line results from its Phase II clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. 15 September 2015
Pharmaceutical
Indian drug major Dr Reddy’s Laboratories has signed a commercialization deal with Australian firm Hatchtech for its innovative prescription head lice product Xeglyze Lotion. 14 September 2015
Biotechnology
Aclaris Therapeutics and Rigel Pharmaceutical have entered into an exclusive, worldwide license agreement for the development and commercialization of Rigel’s JAK inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. 10 September 2015
Pharmaceutical
The US Food and Drug Administration has issued a warning about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is used to treat actinic keratosis. 22 August 2015
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries yesterday announced that the US Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for Ximino (minocycline HCl) extended-release capsules. 20 August 2015
Biotechnology
US biotech company Amgen has reached an agreement to pay $71 million to 48 US states and the District of Columbia over the marketing of Enbrel (etanercept) and Aranesp (darbepoetin alfa). 19 August 2015
Pharmaceutical
KYTHERA Biopharmaceuticals has submitted a Marketing Authorization Application (MAA) in the European Union, seeking approval for ATX-101 (deoxycholic acid) injection. 18 August 2015
Pharmaceutical
The US Food and Drug Administration has approved German pharma major Bayer’s Finacea (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea 4 August 2015
Biotechnology
Amarantus BioScience on Monday said it has partnered with the US Army Institute of Surgical Research and Rutgers to collaborate on developing a treatment of deep burn wounds in adults. 3 August 2015
Pharmaceutical
AbbVie says that its mega blockbuster drug Humira (adalimumab) is now approved in the European Union for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa). 3 August 2015
Biotechnology
Hong Kong-based Bloomage BioTechnology Corp has entered a strategic cooperation with the South Korean biotech company Medytox to establish a joint venture, to be called Medybloom, to develop and promote Type A Botulinum Toxin business in China. 30 July 2015
Pharmaceutical
Almirall has announced the closing of a $15 million in Series C equity investment in privately-held US firm Suneva Medical, an innovative aesthetics leader that markets Bellafill. 29 July 2015
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze